Scleroderma clinical trials at University of California Health
2 in progress, 1 open to eligible people
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
open to eligible people ages 18-75
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
at UCSD
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
Sorry, in progress, not accepting new patients
The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.
at UCLA
Last updated: